IL13 and asthma: Th2-type cytokines, particularly interleukin-13 (IL-13), have been shown to orchestrate airway allergic inflammatory and remodeling processes [5–7], and anti-IL-13 agents have been highlighted for the treatment of asthma cases unresponsive to ICSs.